All In MedTech

Device Trial Radar · NCT01617954

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Last checked: Nov 20, 2026Latest source record: Jan 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

820

Actual

Start

May 2012

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
AgendiaNot on our public-company list
Sponsor type
Industry
First posted
Jun 13, 2012

More device trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Conditions

  • Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

  • MammaPrintDevice

    All subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in recommended adjuvant chemotherapy treatmentTime frame: 30 days

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Maricopa Integrated Health System

    Phoenix, Arizona

52 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.